Clinical Trials for Idiopathic Pulmonary Fibrosis (IPF): Type V Collagen Oral Solution

In 2010, the FDA granted ImmuneWorks initiated a Phase I Clinical Trial of our Type V Collagen product (IW001) in patients suffering from idiopathic pulmonary fibrosis (IPF). This clinical trial was designed to test ImmuneWorks’ oral treatment in IPF patients who have demonstrated autoimmunity to Type V collagen. The trial was successfully completed in late 2012.

For more information about ImmuneWorks’ FDA-approved IPF clinical trial, please visit